Header Logo

Connection

Theo Manschreck to Schizophrenia

This is a "connection" page, showing publications Theo Manschreck has written about Schizophrenia.
Connection Strength

6.661
  1. Shahzade C, Chun J, DeLisi LE, Manschreck TC. Patterns in adolescent cannabis use predict the onset and symptom structure of schizophrenia-spectrum disorder. Schizophr Res. 2018 07; 197:539-543.
    View in: PubMed
    Score: 0.611
  2. Boshes RA, Manschreck TC. Less is more Redux: Scheduled intermittent dosing to protect/prevent cognitive deterioration in schizophrenia. Med Hypotheses. 2016 May; 90:79-81.
    View in: PubMed
    Score: 0.527
  3. Manschreck TC, Chun J, Merrill AM, Maher BA, Boshes RA, Glatt SJ, Faraone SV, Tsuang MT, Seidman LJ. Impaired motor performance in adolescents at familial high-risk for schizophrenia. Schizophr Res. 2015 Oct; 168(1-2):44-9.
    View in: PubMed
    Score: 0.502
  4. Osser DN, Roudsari MJ, Manschreck T. The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia. Harv Rev Psychiatry. 2013 Jan-Feb; 21(1):18-40.
    View in: PubMed
    Score: 0.422
  5. Manschreck TC, Merrill AM, Jabbar G, Chun J, Delisi LE. Frequency of normative word associations in the speech of individuals at familial high-risk for schizophrenia. Schizophr Res. 2012 Sep; 140(1-3):99-103.
    View in: PubMed
    Score: 0.409
  6. Manschreck TC, Boshes RA. The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiatry. 2007 Sep-Oct; 15(5):245-58.
    View in: PubMed
    Score: 0.291
  7. Lenzenweger MF, Maher BA, Manschreck TC. Paul E. Meehl's influence on experimental psychopathology: fruits of the nexus of schizotypy and schizophrenia, neurology, and methodology. J Clin Psychol. 2005 Oct; 61(10):1295-315.
    View in: PubMed
    Score: 0.255
  8. Manschreck TC, Maher BA, Candela SF. Earlier age of first diagnosis in schizophrenia is related to impaired motor control. Schizophr Bull. 2004; 30(2):351-60.
    View in: PubMed
    Score: 0.226
  9. Boshes RA, Manschreck TC. Review of antipsychotic medication administration: a proposal of intermittent dosing. Schizophr Bull. 2002; 28(2):203-22.
    View in: PubMed
    Score: 0.197
  10. Manschreck TC, Maher BA, Candela SF, Redmond D, Yurgelun-Todd D, Tsuang M. Impaired verbal memory is associated with impaired motor performance in schizophrenia: relationship to brain structure. Schizophr Res. 2000 May 25; 43(1):21-32.
    View in: PubMed
    Score: 0.176
  11. Manschreck TC, Maher BA, Winzig L, Candela SF, Beaudette S, Boshes R. Age disorientation in schizophrenia: an indicator of progressive and severe psychopathology, not institutional isolation. J Neuropsychiatry Clin Neurosci. 2000; 12(3):350-8.
    View in: PubMed
    Score: 0.171
  12. Manschreck TC, Redmond DA, Candela SF, Maher BA. Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia. J Neuropsychiatry Clin Neurosci. 1999; 11(4):481-9.
    View in: PubMed
    Score: 0.160
  13. White MS, Maher BA, Manschreck TC. Hemispheric specialization in schizophrenics with perceptual aberration. Schizophr Res. 1998 Aug 17; 32(3):161-70.
    View in: PubMed
    Score: 0.156
  14. Manschreck TC, Maher BA, Beaudette SM, Redmond DA. Context memory in schizoaffective and schizophrenic disorders. Schizophr Res. 1997 Aug 29; 26(2-3):153-61.
    View in: PubMed
    Score: 0.146
  15. Pillai A, Schooler NR, Peter D, Looney SW, Goff DC, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz A, Miller DD, Severe JB, Wilson DR, Ames D, Bustillo J, Kane JM, Buckley PF. Predicting relapse in schizophrenia: Is BDNF a plausible biological marker? Schizophr Res. 2018 03; 193:263-268.
    View in: PubMed
    Score: 0.144
  16. Buckley PF, Schooler NR, Goff DC, Kopelowicz A, Lauriello J, Manschreck TC, Mendelowitz A, Miller DD, Wilson DR, Ames D, Bustillo JR, Kane JM, Looney SW. Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study. Psychiatr Serv. 2016 12 01; 67(12):1370-1372.
    View in: PubMed
    Score: 0.135
  17. Manschreck TC, Redmond DA, Beaudette SM. Clozapine in the back wards. Ann Clin Psychiatry. 1994 Dec; 6(4):215-25.
    View in: PubMed
    Score: 0.120
  18. Buckley PF, Schooler NR, Goff DC, Hsiao J, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz AJ, Miller del D, Severe JB, Wilson DR, Ames D, Bustillo J, Mintz J, Kane JM. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. Schizophr Bull. 2015 Mar; 41(2):449-59.
    View in: PubMed
    Score: 0.116
  19. Chun J, Karam ZN, Marzinzik F, Kamali M, O'Donnell L, Tso IF, Manschreck TC, McInnis M, Deldin PJ. Can P300 distinguish among schizophrenia, schizoaffective and bipolar I disorders? An ERP study of response inhibition. Schizophr Res. 2013 Dec; 151(1-3):175-84.
    View in: PubMed
    Score: 0.112
  20. Thermenos HW, Whitfield-Gabrieli S, Seidman LJ, Kuperberg G, Juelich RJ, Divatia S, Riley C, Jabbar GA, Shenton ME, Kubicki M, Manschreck T, Keshavan MS, DeLisi LE. Altered language network activity in young people at familial high-risk for schizophrenia. Schizophr Res. 2013 Dec; 151(1-3):229-37.
    View in: PubMed
    Score: 0.112
  21. Goff DC, McEvoy JP, Citrome L, Mech AW, Bustillo JR, Gil R, Buckley P, Manschreck TC, Achtyes ED, Macklin EA. High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study. J Clin Psychopharmacol. 2013 Aug; 33(4):485-90.
    View in: PubMed
    Score: 0.110
  22. Scala S, Pousada A, Stone WS, Thermenos HW, Manschreck TC, Tsuang MT, Faraone SV, Seidman LJ. Verbal and visual-spatial memory impairment in youth at familial risk for schizophrenia or affective psychosis: a pilot study. Schizophr Res. 2013 Mar; 144(1-3):122-8.
    View in: PubMed
    Score: 0.106
  23. Boshes RA, Manschreck TC, Konigsberg W. Genetics of the schizophrenias: a model accounting for their persistence and myriad phenotypes. Harv Rev Psychiatry. 2012 May-Jun; 20(3):119-29.
    View in: PubMed
    Score: 0.101
  24. Manschreck TC, Leighton AH. Reducing disability in mood disorders and schizophrenia. Hosp Community Psychiatry. 1992 Feb; 43(2):179-80.
    View in: PubMed
    Score: 0.099
  25. Stroup TS, Appelbaum PS, Gu H, Hays S, Swartz MS, Keefe RS, Kim SY, Manschreck TC, Boshes RA, McEvoy JP, Lieberman JA. Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study. Schizophr Res. 2011 Aug; 130(1-3):47-52.
    View in: PubMed
    Score: 0.094
  26. Manschreck TC, Maher B, Celada MT, Schneyer M, Fernandez R. Object chaining and thought disorder in schizophrenic speech. Psychol Med. 1991 May; 21(2):443-6.
    View in: PubMed
    Score: 0.094
  27. Manschreck TC, Keuthen NJ, Schneyer ML, Celada MT, Laughery J, Collins P. Abnormal involuntary movements and chronic schizophrenic disorders. Biol Psychiatry. 1990 Jan 15; 27(2):150-8.
    View in: PubMed
    Score: 0.086
  28. Chan RC, Wang Y, Wang L, Chen EY, Manschreck TC, Li ZJ, Yu X, Gong QY. Neurological soft signs and their relationships to neurocognitive functions: a re-visit with the structural equation modeling design. PLoS One. 2009 Dec 24; 4(12):e8469.
    View in: PubMed
    Score: 0.086
  29. Lenzenweger MF, Miller AB, Maher BA, Manschreck TC. Schizotypy and individual differences in the frequency of normal associations in verbal utterances. Schizophr Res. 2007 Sep; 95(1-3):96-102.
    View in: PubMed
    Score: 0.072
  30. Manschreck TC, Ames D, Maher BA, Schneyer ML. Impoverished written responses and negative features of schizophrenia. Percept Mot Skills. 1987 Jun; 64(3 Pt 2):1163-9.
    View in: PubMed
    Score: 0.072
  31. Goff DC, Lamberti JS, Leon AC, Green MF, Miller AL, Patel J, Manschreck T, Freudenreich O, Johnson SA. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology. 2008 Feb; 33(3):465-72.
    View in: PubMed
    Score: 0.071
  32. Maher BA, Manschreck TC, Linnet J, Candela S. Quantitative assessment of the frequency of normal associations in the utterances of schizophrenia patients and healthy controls. Schizophr Res. 2005 Oct 15; 78(2-3):219-24.
    View in: PubMed
    Score: 0.064
  33. Stroup S, Appelbaum P, Swartz M, Patel M, Davis S, Jeste D, Kim S, Keefe R, Manschreck T, McEvoy J, Lieberman J. Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophr Res. 2005 Dec 01; 80(1):1-8.
    View in: PubMed
    Score: 0.064
  34. Manschreck TC, Maher BA, Waller NG, Ames D, Latham CA. Deficient motor synchrony in schizophrenic disorders: clinical correlates. Biol Psychiatry. 1985 Sep; 20(9):990-1002.
    View in: PubMed
    Score: 0.063
  35. Manschreck TC, Ames D. Neurologic features and psychopathology in schizophrenic disorders. Biol Psychiatry. 1984 May; 19(5):703-19.
    View in: PubMed
    Score: 0.058
  36. Manschreck TC, Maher BA, Rucklos ME, Vereen DR. Disturbed voluntary motor activity in schizophrenic disorder. Psychol Med. 1982 Feb; 12(1):73-84.
    View in: PubMed
    Score: 0.049
  37. Manschreck TC. Current concepts in psychiatry: schizophrenic disorders. N Engl J Med. 1981 Dec 31; 305(27):1628-32.
    View in: PubMed
    Score: 0.049
  38. Manschreck TC, Maher BA, Rucklos ME, Vereen DR, Ader DN. Deficient motor synchrony in schizophrenia. J Abnorm Psychol. 1981 Aug; 90(4):321-8.
    View in: PubMed
    Score: 0.048
  39. Manschreck TC. Placebo studies: lessons from psychiatric research. Psychiatr Ann. 2001 Feb; 31(2):130-6.
    View in: PubMed
    Score: 0.046
  40. Maher BA, Manschreck TC, Yurgelun-Todd DA, Tsuang MT. Hemispheric asymmetry of frontal and temporal gray matter and age of onset in schizophrenia. Biol Psychiatry. 1998 Sep 15; 44(6):413-7.
    View in: PubMed
    Score: 0.039
  41. Blyler CR, Maher BA, Manschreck TC, Fenton WS. Line drawing as a possible measure of lateralized motor performance in schizophrenia. Schizophr Res. 1997 Jul 25; 26(1):15-23.
    View in: PubMed
    Score: 0.036
  42. Maher BA, Manschreck TC, Redmond D, Beaudette S. Length of illness and the gradient from positive to negative semantic priming in schizophrenic patients. Schizophr Res. 1996 Nov 15; 22(2):127-32.
    View in: PubMed
    Score: 0.034
  43. Manschreck TC. Delusional disorder: the recognition and management of paranoia. J Clin Psychiatry. 1996; 57 Suppl 3:32-8; discussion 49.
    View in: PubMed
    Score: 0.032
  44. Welch J, Manschreck T, Redmond D. Clozapine-induced seizures and EEG changes. J Neuropsychiatry Clin Neurosci. 1994; 6(3):250-6.
    View in: PubMed
    Score: 0.028
  45. Manschreck TC, Maher BA, Rosenthal JE, Berner J. Reduced primacy and related features in schizophrenia. Schizophr Res. 1991 Jul-Aug; 5(1):35-41.
    View in: PubMed
    Score: 0.024
  46. Manschreck TC, Maher BA, Hoover TM, Ames D. The type--token ratio in schizophrenic disorders: clinical and research value. Psychol Med. 1984 Feb; 14(1):151-7.
    View in: PubMed
    Score: 0.014
  47. Manschreck TC. Psychopathology of motor behavior in schizophrenia. Prog Exp Pers Res. 1983; 12:53-99.
    View in: PubMed
    Score: 0.013
  48. Latham C, Holzman PS, Manschreck TC, Tole J. Optokinetic nystagmus and pursuit eye movements in schizophrenia. Arch Gen Psychiatry. 1981 Sep; 38(9):997-1003.
    View in: PubMed
    Score: 0.012
  49. Manschreck TC, Petri M. The atypical psychoses. Cult Med Psychiatry. 1978 Sep; 2(3):233-68.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.